SORT BY Relevancy
OvaNext is a next generation (next-gen) sequencing panel that simultaneously analyzes 23 genes that contribute to increased risk for breast, ovarian and/or uterine cancers.
Ambry utilizes next generation sequencing to offer a comprehensive genetic testing panel for hereditary gynecologic cancers (cancer of the breast, ovary and/or uterus), including BRCA1 and BRCA2.
An overview of Ambry's revolutionary form of genetic testing which allows scientists to diagnose many different diseases using far less tests than before. Scientists can now diagnose multiple different diseases with far fewer tests, easing the burden on patients and their families both emotionally as well as financially.
Join Host Live Chats
- sun752 (1 chatters)